Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Shenzhen Hepalink Pharmaceutical Co Ltd's subsidiary to acquire SPL Acquisition Corp. from American Capital, Ltd and other shareholders


Thursday, 26 Dec 2013 07:00pm EST 

American Capital, Ltd:Shenzhen Hepalink Pharmaceutical Co Ltd will fully acquire SPL Acquisition Corp. (SPL) for cash consideration of $222,651,700, or about 1,368,862,700 yuan, through its US-based wholly owned subsidiary, HEPALINK USA INC.Shenzhen Hepalink Pharmaceutical will acquire SPL from American Capital, Ltd., American Capital Equity I, LLC, American Capital Equity II, LP, and 13 individual shareholders.Shenzhen Hepalink Pharmaceutical will also pay $108,173,300, or about 665,049,400 yuan to the creditors of SPL to pay off part of the debt of SPL.American Capital, Ltd holds a 51.06 pct stake in SPL Acquisition Corp. 

Company Quote

15.46
-0.03 -0.19%
28 Aug 2014